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Abstract:
Objectives: To revise the epidemiology,
pathogenesis, diagnosis, treatment and
prognosis in gallbladder carcinomas. To revise
the role of molecular pathology in this entity
and its importance in therapeutic perspectives.
Methods: A revision of all the articles published
between 2006-2016 and indexed in PubMed
containing the keywords "gallbladder", "cancer",
"carcinoma", "diagnosis", "treatment",
"perspectives" and/or "targeted therapy " was
carried out.
Results: The incidence of gallbladder carcinoma
varies greatly depending on the geographical
area [considered]. Its natural history is related to
chronic inflammation and cholelithiasis is its
main risk factor. The diagnosis is usually made
at a late stage and, despite the treatment, it
shows/has a poor prognosis. Changes in p53
and K-Ras are common. Modulation of
inflammation is postulated as a therapeutic
alternative.
Conclusions: Gallbladder carcinoma is a
neoplasm with an aggressive course. The
improvement in its prognosis needs of the
control of risk factors and early diagnosis
supported by imaging tests. New surgical
techniques and the description of new





Gallbladder carcinoma (GBC) is the most com-
mon malignant neoplasm of the biliary tract (1).
It is also the most aggressive and has the worst
survival rates within its group. This is the re-
sult of / this is due to the rapid evolution of the
tumour, the nonspecific symptomatology that
usually accompanies this growth, the lack of
screening tests, and the problems with diagnos-
tic imaging. Complete surgical resection is the
curative alternative, but it is only feasible in 10%
of the cases (2). Surgical morbimortality and
bed recurrence rates are high among patients
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with early carcinomas susceptible to this type of
intervention (3). The objective of this text is to
revise the epidemiology, pathogenesis, pathol-
ogy, treatment and perspectives of GBC.
Material and methods
A revision of the literature on GBC was per-
formed using PubMed. The words "gallbladder",
"cancer", "carcinoma", "diagnosis", "treatment",
"perspectives" and / or "targeted therapy" were
used as keywords. The results were filtered by
using only revisions published in the last decade
(2006-2016). Secondary references steaming
from revisions and original articles indexed in
this database were filtered manually. Only rele-
vant studies focused on targeted therapy or per-
spectives on the disease were included. Clinical
cases and communications on infrequent histo-
logical variants were not included.
Epidemiology
GBC is the most globally common malignant
neoplasm of the biliary tree. It is three times
more common in women than men, with a mean
age at diagnosis of 72 years. The pathogenesis of
GBC has not been clarified, but multiple factors
are known to be involved in its development (1)
(2). Among them, cholelithiasis seems to be
most prominent.
Demographic factors
The incidence of GBC varies according to the ge-
ographical area [considered]. Rates for high-risk
regions such as Chile (27 / 100,000), India (21,5 /
100,000), Bolivia (15,100,000) or Pakistan (13,8
/ 100,000) are much higher than those found in
low-risk areas . The United States, Canada, and
New Zealand have incidence rates of 0.4-0-8 /
100,000 in men, and 0.6-1.4 / 100,000 in women
(1,3,4). Western European countries, including
Spain, are considered regions of risk, although
with a lower presentation frequency than Asia
and the Andean region.
These variations have been attributed to genetic
differences and the lifestyle of the population.
Diets high in carbohydrates and red meat in-
crease risk (5). The same thing occurring with
obesity, which increases the risk of GBC 1.59
times in women, and 1.09 in men (1). The link
between being multiparous and GBC is not well
understood. It is unknown if it is directly related
to carcinogenesis or whether it is secondary to
the higher frequency of cholelithiasis in this pop-
ulation group.
Gallblader disease
Cholelithiasis is the disease that shows the high-
est correlation with the development of GBC.
Up to 80% of patients with this neoplasm have
lithiasis (3,6). The risk is higher in single-stone
lithiasis with a stone greater than 3 cm in diame-
ter. In these cases, a relative risk 10 times higher
than the general population has been described
(1,2). The composition of the calculus/stone has
shown no positive correlation with the develop-
ment of GBC.
Cholelithiasis stimulates the appearance of
chronic inflammatory phenomena that could favour
epithelial transformation. Initially, dysplasia
would occur on the biliary or metaplastic intesti-
nal / pseudopyloric epithelium. Then/Therefore,
the persistence of the damage could promote neo-
plastic development.
The term "porcelain gallbladder" describes
two distinct patterns: diffuse or selective intra-
mural calcification. The patched or selective
pattern seems more associated with the occur-
rence of GBC than the diffuse pattern. Vesicular
polyps, especially when they are unique, sessile
and larger than 10mm are also a risk factor (2).
Abnormalities in the pancreaticobiliary junction
and congenital cysts may favour the ascent and
remanence of pancreatic secretions in the biliary
tract and gallbladder. This stimulates, as in the
case of cholelithiasis, chronic inflammatory phe-
nomena that trigger precancerous changes in the
mucosa. The same happens with the retention of
secretions in primary sclerosing cholangitis.
Other risk factors
Hormone therapy has been linked to GBC (1).
This could be related to/could be the result of/could
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be due to its prolitogenic role, but also to the di-
rect stimulation of epithelial proliferation and
transformation. The association with other drugs
and heavy metals has been described, although
its contribution to the development of GBC is
uncertain. Carriers of Salmonella and Helicobac-
ter (1,6) in the biliary tract have been linked with
a higher GBC rate. Bacterial degradation of bile
salts is believed to be carcinogenic.
Pathogenesis
Two key pathways have been proposed in GBC
development: the dysplasia-carcinoma sequence
and the adenoma-carcinoma sequence. In both
cases, the transformed epithelium may be that
of the gallbladder itself, or intestinal / pseudopy-
loric metaplastic mucosa. This last point is im-
portant considering that up to 80% of GBCs are
adenocarcinomas.
In the dysplasia-carcinoma sequence, the ini-
tial metabolic frame is chronic inflammation (7-
9). When this is associated with biliopancre-
atic junction abnormalities, it can lead to hyper-
plasia of the biliary epithelium. Alternatively,
when it appears in the cholelithiasis, it normally
promotes the appearance of foci of intestinal /
pseudopyloric metaplasia. These lesions may
progress and stimulate the genesis of dysplastic
areas. These premalignant lesions, if the asso-
ciated factors are maintained and elapsed long
enough, may degenerate into carcinomas (7).
Figure 7.1: Modelo de diseminación y carcinogé-
nesis en la vesícula biliar
During chronic inflammation, multiple cy-
tokines, reactive oxygen species, prostaglandins,
growth factors and the like are synthesied in low
amounts, but in a sustained manner. This favours
the appearance of mutations, epigenetic and/or
post-translational modifications in tumour sup-
pressor genes and oncogenes (8,10).
The tumour necrosis factor (TNF) is one
of the most prominent mediators. From early
stages, it modulates not only macrophagic activ-
ity and also stimulates angiogenesis and expres-
sion of growth factor receptors, such as EGFR.
Chemokines such as CXCL12 have been ob-
served to be increased in GBC. The same applies
for MUC5AC, prostaglandins, and COX-2 ac-
tivity. Therefore, the use of anti-COX2 drugs
has been proposed as a modulator of chronic
vesicular inflammation and as a possible pre-
ventive/adjuvant treatment in GBC (7,8). Se-
quence changes in p53, tumour suppressor gene
(TSG), are present in one-third of the patients
with cholelithiasis without GBC. The percent-
age increases to 52.4% when there is neoplasia.
Therefore, the loss of p53 is considered an early
change in GBC (7). Changes in the Ras family
are less frequent among preneoplastic lesions.
However, K-Ras is mutated in 39-59% of GBCs
(8).
The loss of heterozygosity (LOH) occurs in sev-
eral loci in GBC. Early events are considered
changes in 5q. LOH at 3p and 9p is associated
with progression. Other modifications/changes,
described but probably later/at a late stage, occur
in 13q and 18q (7).
The methylation of TSG promoters in GBC
is a probable but still virtually unexplored event.
(11) MiRNAs are molecules whose deregulation
can lead to the onset of cancer. In this sense, al-
though not fully studied, high levels of miR-155
have been associated with worse survival rates
in GBC (8).
In the adenoma-carcinoma sequence, more
uncommon in GBC, the steps are less well-known
(7). The polyps with the highest risk of transfor-
mation are those already described in previous
sections.
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Figure 7.2: Cambios asociados a inflamación
crónica y CVB.
Anatomic pathology
A significant fraction of GBCs is diagnosed in-
cidentally after cholecystectomy. The anato-
mopathological study of the piece is indicated in
all cases. In addition, if macroscopic lesions sug-
gestive of BIC are observed during the operation,
the intraoperative study is obligatory in order to
assess the need to extend the initial surgery.
Macroscopically, between 10-37% of GBCs
show features either compatible with chronic
cholecystitis or not quite suggestive of a neoplas-
tic formation process. In all other cases, suspi-
cious areas are identified in the surgical speci-
men. These may be, as in imaging techniques:
light occupying masses, polypoid lesions or wall
thickenings. Around a 60% of GBCs settle in
the fundus of the gallbladder, 30% in the body
and 10% in the neck. White nodular lesions are
the most commonly associated with intrahepatic
invasion (1,2).
More than 80% of GBCs are adenocarcinomas,
two-thirds of which are poorly or moderately dif-
ferentiated. Other much more infrequent but also
known histological variants are papillary, muci-
nous and adenosquamous carcinomas. Other
histological types have been described, but their
frequency is minimal and, therefore, are not well
documented.
Clinical presentation and diagnosis
The symptoms of GBC are often nonspecific,
which delays the diagnosis. The most common
manifestations are chronic cholecystitis: epigas-
tric pain, dyspepsia, precocious satiety, etc. In
some cases, these may be accompanied by the
constitutional syndrome. In this situation, hy-
porexia and weight loss are the most striking
signs. Biliary obstruction is related to advanced
disease. Digestive haemorrhage and high in-
testinal obstruction are other possible pictures in
the beginning, although their frequency is much
lower (2,6).
Two-thirds of treated GBCs are unsuspected
carcinomas (2). The remaining third, known
or suspected GBC, is diagnosed preoperatively
through imaging tests. Among them, the most
outstanding are an ultrasound (transabdominal
or endoscopic), computed tomography (CT) and
magnetic resonance imaging (MRI). Other less
used are PET and cholangiography (12). Those
patterns more commonly related to GBC are col-
lected/can be observed in image 3 (12,13). The
image also shows its frequency of presentation
and the problems of differential diagnosis that
each of these forms poses/proper of each of these
forms.
Figure 7.3: Presentación clínica y pruebas de
imagen en CVB
Tumor markers
Tumour markers cannot be used as a diagnostic
tool in GBC. However, in patients suspected of
the disease due to imaging / clinical results, high
levels of CEA, CA 19.9 and/or CA 125 may be
highly suggestive of the disease (2).
Staging
There are different staging systems in GBC. These
include Nevin Staging System, Staging System
of the Japanese Society of Biliary Surgery and
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TNM Classification of the American Joint Com-
mittee on Cancer (AJCC). These are presented
in table 2 (1).
Treatment
The GBC treatment may vary according to its
spread. Between 0.3 and 3% of all cholecys-
tectomies performed due to cholelithiasis are
reported as neoplasia. In this case, which is fre-
quently approached with laparoscopy, up to a
17% of patients recur.
If GBC is suspected or confirmed, an open
approach is necessary. The surgical extent will
depend on the spreading of the hepatic injury
and the existence of adenopathies. Thus, in T1a
stage, simple cholecystectomy is curative. In
T1b, cholecystectomy may be associated with
segmentectomy (IVb and V) and lymphadenec-
tomy. In T2 tumours, this is the appropriate
procedure in all cases. T3 GBC needs aggressive
surgery. Cholecystectomy plus lymphadenec-
tomy and right hepatectomy may be suggested.
If other structures were affected, this technique
would be modified according to the circumstances.
The T4 carcinomas are not subsidiary of surgi-
cal treatment (1, 6). Despite the previous in-
dications, there is no agreement on the initial
approach of this neoplasia. Imaging tests and di-
agnostic laparoscopy may help to evaluate the ex-
tent and may determine the technique to choose.
The GBC medical treatment has been little
investigated. The therapy may have either the
intention of healing or palliating. Three possi-
ble scenarios are presented: post-surgery single
adjuvant therapy or therapy with radiation; unre-
sectable, not spread disease with or without radi-
ation therapy; and, lastly, palliative chemother-
apy in metastatic disease.
In the case of post-surgery adjuvant therapy, a
recent meta-analysis shows a possible benefit of
chemotherapy for patients with a high risk of
metastases. That is, those with a wider tumour
extent, especially if accompanied by adenopathies.
However, it does not clarify the role of adju-
vant therapy for low-risk patients. Among those
benefiting from the cytotoxic treatment, there
are no preferential instructions. Gemcitabine-
cisplatin or fluoropyrimidine are generally ap-
plied. In the case of an unresectable disease,
previous chemotherapy regimens can be accom-
panied by radiation therapy. In the scenario of a
metastatic disease, palliative chemotherapy /be-
comes the only alternative. Radiation therapy in
GBC has been little evaluated and the results ob-
tained are dissimilar. External radiation therapy
might temporarily stop the local-regional spread-
ing. Brachytherapy with Ir-192 might be useful
for palliating obstructive symptoms secondary
to biliary tract infiltration.
Figure 7.4: Radioterapia y tratamiento sistémico
para CVB
Prognosis
The gallbladder cancer prognosis is bleak. Its
manifestations are usually unspecific and appear
in spread disease. Five-year survival rates af-
ter diagnosis reach 5%. Aggressive surgery im-
proves the overall survival, but five-year recur-
rence rates after complete resection reach 40-
60%. Poor prognostic factors for GBC include
age, jaundice, palpable mass, T and N stage, the
hepatic extent of the disease, squamous cell car-
cinoma, squamous adenocarcinoma or small cell
adenocarcinoma. Tumour markers have been
proposed to be included in this list, as well as
certain genetic and epigenetic changes. However,
the evidence is scarce and needs to be corrobo-
rated.
Conclusions
• GBC incidence varies greatly depending
on the region [considered]. Some of the
risk factors are age, gender, obesity, gall-
bladder disease, abnormalities of the pan-
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creaticobiliary tract and exposure to cer-
tain drugs and infectious agents.
• Chronic inflammation is linked to GBC
pathogenesis. Maintained synthesis of in-
flammatory mediators may favour carcino-
genesis through TSG inactivation and onco-
genes inactivation. Events such as losing
of p53 and K-ras mutations are common.
• Clinical findings of GBC are unspecific
and, usually, late.
• There are no recommendations for local
and systemic treatment of GBC. Surgery
and radiation therapy are useful for re-
gional control. In unresectable or metastatic
cases, chemotherapy regimens based in
gemcitabine are the most employed.
• Adenocarcinoma is the most usual histo-
logical variant.
• GBC prognosis is bleak. KRAS, EGFR,
BRAF and HER 2 are thought as a thera-
peutic target.
• Several ongoing clinical trials study the
improvement in survival rates when con-
fronting conventional chemotherapy to com-
bined regimens with antiEGFR (cetuximab,
erlotinib) /antiBRAF (selumetinib). VEGF
has been observed to be overexpressed in
biliary tract neoplasias. Thus, employ-
ment of angiogenesis inhibitors is also pre-
sented as a therapeutical alternative (1)
• Control of chronic inflammation may help
to prevent/treat the biliary tract neoplasias.
Thus, COX-2 inhibitors may be useful.
• Apart from CEA, Ca-125 and CA 19-9,
the utility of markers such as CA242 and
CA199 has been proposed for the moni-
toring and treatment of patients with GBC
(14).
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